Genmab — Marts 2019
-
"Daratumumab appears to be the “gift that keeps on giving” to the myeloma community. " http://www.ascopost.com/issues/march-25-2019/benefit-of-adding-daratumumab-to-initial-therapy-in-multiple-myeloma/
-
De anonyme har sat den i bakgear...
-
Ja vi snart se at få RoTOR`en sat igang så der kan blive kan blive lift-off..:-D
-
Håber I forstår ellers er her der skulle stå:Ja vi må snart se at få RoTOR´en igang så vi kan få liftoff på kursen.
-
Jo men ligger turboen ikke i RoTOR´en?
-
3 TTT er Toyota turbo targa
-
Merck withdrew this Keytruda/Dara trial. Never started it actually. https://clinicaltrials.gov/ct2/history/NCT03221634?A=1&B=2&C=merged
-
-
-
God morgen
-
Investtech: Genmab har brudt op gennem loftet i en faldende trendkanal på mellemlang sigt. Dette indikerer i første omgang svagere faldende takt, eller indledning til en mere horisontal udvikling. Aktien gav købssignal fra en omvendt-hovede-og-skuldre-formation ved bruddet op gennem modstanden ved 1103. Videre stigning til 1571 eller mere er signaleret. Aktien nærmer sig støtten ved cirka 1110 kroner, noget der kan give en reaktion op. Aktien anses samlet set teknisk positiv på mellemlang sigt.
)Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind